On July 1, 2025, the initiation meeting for the Phase I clinical trial of IBR900 cellular injection—developed by ImmuneCell BioRay (Hangzhou) Co., Ltd.—for treating B-cell non-Hodgkin lymphoma was successfully held at Ruijin Hospital, Shanghai Jiao…
Dato DXd (datopotamab deruxtecan) has received U.S. FDA approval – a breakthrough milestone announced jointly by Daiichi Sankyo and AstraZeneca on June 23, 2025. The drug is indicated for the treatment of adults with locally…
— Reported by DengYueMed On June 24, 2024, Bio-Thera Solutions, Ltd. announced that its anti VEGF humanized monoclonal antibody BAT5906 has successfully met the primary endpoint in a pivotal Phase III clinical trial for the…
Molecular Glues: Unique Mechanism Of Action Wide Market Prospects Earlier this year, AbbVie announced a partnership with biotech company Neomorph for more than $1.6 billion to develop novel molecular glues protein degraders on multiple targets…
Novo Nordisk announced that its innovative growth hormone analogue Sogroya® (somapacitan) has been approved by the US Food and Drug Administration (FDA) for the treatment of growth hormone deficiency (GHD) in adults and children. As…
In a world still grappling with neglected tropical diseases, Impavido (generic name: miltefosine) remains one of the few oral treatments available for leishmaniasis, a parasitic infection that affects millions in impoverished and underserved regions. Despite…
Imdelltra™ (tarlatamab-dlle) represents a significant advancement in the treatment of extensive-stage small cell lung cancer (ES-SCLC), a particularly aggressive form of lung cancer. Developed by Amgen, this novel therapy received accelerated approval from the U.S.…
HYMPAVZI is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for the treatment of hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered…
Fampyra, known generically as fampridine or 4-aminopyridine, is an oral medication approved to improve walking ability in adults with multiple sclerosis (MS) who experience walking disabilities. It functions as a potassium channel blocker, aiming to…
In the ongoing battle against antimicrobial resistance, Fetroja (cefiderocol) has emerged as a promising solution for treating complicated infections caused by multidrug-resistant Gram-negative bacteria. Developed by Shionogi & Co.,Ltd., this innovative siderophore cephalosporin antibiotic has…
Antizol, the brand name for fomepizole, is an essential antidote used in the treatment of ethylene glycol and methanol poisoning. These toxic alcohols are commonly found in antifreeze, solvents, and various household products. Without prompt…
In a significant advancement for multiple myeloma treatment, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Elrexfio™ (elranatamab-bcmm) on August 14, 2023. This bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, developed…
